Best of ASCO - 2014 Annual Meeting

 

Welcome

Allogenic Stem Cell Transplantation

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Allogeneic hematopoietic stem celltransplant (HSCT) after checkpoint inhibitors (ChIs) in classic Hodgkin lymphoma (cHL): Outcome and safety in pooled analysis.

Reyad Dada

e19020

Choosing a reduced intensity conditioning, fludarabine melphalan versus fludarabine busulfan: A meta-analysis and systematic review.

Tania Jain

e19017

Cyclophosphamide (Cy) pharmacogenetics (PGx) in allogeneic stem cell transplant (SCT) patients (pts) receiving Cy, fludarabine, total body irradiation and post-transplant Cy (FluCyTBI-postCy).

Jai Narendra Patel

7058

Development and validation of a risk assessment tool for symptomatic BKV infection.

Ala Abudayyeh

7057

Effect of donor type in patients with AML or MDS undergoing reduced intensity hematopoietic cell transplant.

Nahid Rashid

7059

Fludarabine/cyclophosphamide (Flu/Cy) non-myeloablative allogeneic stem cell transplant for aplastic anemia and hypoplastic myelodysplasia: A single institution experience.

Michelle Alison Levy

e19021

Post-transplant cyclophosphamide (PT-Cy) based haploidentical transplantation (haploHCT) versus matched sibling (MSD) or matched unrelated donor (MUD) reduced intensity conditioning (RIC) HCT for diffuse large b-cell lymphoma (DLBCL): A CIBMTR and EBMT analysis.

Mehdi Hamadani

7056

The relationship between coping strategies and quality of life (QOL) in patients with chronic graft-versus-host disease (cGVHD).

Netana Markovitz

e19016

The role of type I interferon in prophylaxis of graft-versus-host disease.

Erik Thiele Orberg

e19015

Total marrow irradiation (TMI) combined with treosulfan and fludarabine conditioning regimen for chemosensitive advanced multiple myeloma (MM) patients undergoing matched allogeneic stem-cell transplantation: First results of a phase I/II prospective monocentric study (TrRaMM TMI).

Andrea A. Assanelli

e19019